Rui Avelar - 14 Mar 2023 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
Chief Medical Officer and Head of Research & Development
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Issuer symbol
EOLS
Transactions as of
14 Mar 2023
Net transactions value
-$126,237
Form type
4
Filing time
16 Mar 2023, 19:01:50 UTC
Previous filing
27 Jan 2023
Next filing
16 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock Sale $126,237 -14,906 -4.2% $8.47 335,925 14 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units.
F2 The shares were sold in multiple trades at prices ranging from $8.25 to $8.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Chief Medical Officer and Head of Research & Development